Navigation Links
Geron's Telomerase Inhibitor Cancer Drug Demonstrates Good,Pharmacokinetics and Tolerability in Phase I/II Trial

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 12, 2007 - Geron Corporation's (Nasdaq:GERN) telomerase inhibitor cancer drug, GRN163L, has demonstrated good pharmacokinetics and tolerability in its ongoing Phase I/II trial involving patients with chronic lymphocytic leukemia (CLL), according to data presented today by Alan Colowick, M.D., M.P.H., the company's president, oncology, at the Pan Pacific Lymphoma Conference in Maui, Hawaii.

Favorable Pharmacokinetics; Pharmacodynamics Consistent with Expectations

A pharmacokinetic analysis of three patients in the highest dose cohort (cohort 4, 160 mg/m2 IV/week) has shown transient peak plasma concentrations of GRN163L of approximately 10 ug/ml. This and other data indicate that the drug continues to exhibit favorable pharmacokinetic properties that are linear with respect to the doses tested so far.

Up to the current dose levels, no significant changes in telomerase activity or telomere length in the bulk circulating CLL cells of treated patients have been observed. These pharmacodynamic results are consistent with expectations because of the relatively short exposure of CLL cells in patients' blood to concentrations of drug capable of inhibiting telomerase.

Good Tolerability Profile

With dosing and accrual to cohort 4 continuing, patients treated at the current dose levels have tolerated the drug well, and the maximum tolerated dose has not yet been identified. Grade 1-2 partial thromboplastin time (aPTT) prolongation has been observed, and one patient each has experienced Grade 3 and Grade 4 thrombocytopenia.

Clinical Course

One patient in cohort 4 has completed two cycles of treatment, and stable disease has been observed. A second patient has had clinical findings consistent with tumor lysis syndrome, a transient metabolic abnormality resulting from the rapid destruction of malignant cells. This patient experienced a transie
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
2. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
3. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
4. Telomerase Presentations at the AACR 2007 Annual Meeting
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
7. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
8. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
9. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
10. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:5/17/2013)... NEW YORK , May 17, 2013 /PRNewswire-iReach/ -- ... for Advanced Cardiac Life Support (ACLS), Pediatric Advanced Life ... offering free PALS, BLS and ACLS online ... free manuals, people simply need to build an account ... review materials for these programs, United Medical Education is ...
(Date:5/17/2013)... , May 17, 2013  Serving a region of 650,000 ... , Caribbean Imaging and Radiation Therapy (CIRT, ... capabilities with the acquisition of an Elekta Versa HD™ system, ... HD offers clinicians the versatility to deliver conventional therapies to ... also enabling treatment of highly complex cancers that require extreme ...
(Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
Breaking Medicine Technology:ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... Data also showed differences in gastrointestinal and lipid ... among study population, PRINCETON, N.J., Feb. 6 ... announced results from the CASTLE study, in which,300 ... 100 mg of,ritonavir (REYATAZ/r) showed similar antiviral efficacy ...
... is,a life saving treatment option for people with ... far exceeds the supply. Each year,only about one-third ... receive one, and,some patients die while waiting. In ... how the current system for allocating donor,organs in ...
Cached Medicine Technology:CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 2CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 4CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 5CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 6Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System 2Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System 3
(Date:5/18/2013)... May 18, 2013 The Ayurvedic practitioner ... education institution in the West. Program is available in ... Ayurveda is a healing modality practiced for over 5,000 ... is considered that health begins when an individual lives ... of their individual needs. Ayurveda aims to heal an ...
(Date:5/18/2013)... Meadows, IL (PRWEB) May 18, 2013 ... urges Oregon Gov. John A. Kitzhaber, M.D., (D) to ... state law by prohibiting minors under the age of ... Oregon would become the third state in the nation ... already have enacted similar indoor tanning bans for minors. ...
(Date:5/18/2013)... 18, 2013 Spectrum Surgical Instruments ... May 17-22 in Austin, TX where thousands of ... and networking opportunities. , Spectrum Surgical/STERIS will ... scope repair capabilities and certified pre-owned equipment. ... information on proper instrument care of flexible endoscopes. ...
(Date:5/18/2013)... 2013 John Ravera, D.D.S., a Newport ... a new member to his dental team, Courtney Marino. , ... field for over 10 years. She received her degree from ... elected a member of Sigma Pi Alpha, a national honor ... working with patients of all ages, helping them understand the ...
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 ... latest update to consumers about transvaginal mesh ... federal court Resource4thePeople reports that plaintiffs have ... to court documents. , The rulings came ... District Court in the Southern District of ...
Breaking Medicine News(10 mins):Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:2013 Alleged Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Defendants Ordered to Provide Testimony, Documents 2Health News:2013 Alleged Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Defendants Ordered to Provide Testimony, Documents 3Health News:2013 Alleged Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Defendants Ordered to Provide Testimony, Documents 4
... as a second-line therapy had a significantly improved ... treated with topotecan (Hycamtin), according to research presented ... in Amsterdam, hosted by the International Association for ... showed significant improvements in tumor shrinkage, symptom control ...
... School of Public Health (HSPH), Massachusetts Institute of Technology ... Providence Health & Services have found that expanding low ... use, reduces financial strain on covered individuals, and improves ... study to evaluate the impact of insuring the uninsured ...
... teaches children about fitness and encourages them to live ... has statistical evidence that sports participation is also beneficial ... Keren Shahar, a Ph.D. student at Tel Aviv University,s ... supervision of Prof. Tammie Ronen and Prof. Michael Rosenbaum, ...
... WEDNESDAY, July 6 (HealthDay News) -- Move over, Lyme disease: ... of the country, and this one can kill. Known ... that attacks blood cells, causing flu-like symptoms that can make ... caused by bacteria, babesia microti parasites are carried by deer ...
... , WEDNESDAY, July 6 (HealthDay News) -- The next time you ... this: The high you get from eating all that fat may ... marijuana. The same mechanism that gives pot smokers the ... -- appears to help explain why people like fat so much, ...
... Amsterdam - 6 July, 2011 - Elsevier, a ... products and services, today announced the availability of ... SciVal Experts. The tool seamlessly links opportunities within ... profiles within SciVal Experts, automating the process of ...
Cached Medicine News:Health News:Medicaid increases use of health care, decreases financial strain, improves health 2Health News:Medicaid increases use of health care, decreases financial strain, improves health 3Health News:Leaving anger on the field 2Health News:A Deadly New Reason to Avoid Deer Ticks 2Health News:A Deadly New Reason to Avoid Deer Ticks 3Health News:Binge Eating May Be a High All Its Own 2Health News:Binge Eating May Be a High All Its Own 3Health News:Elsevier matches funding opportunities to researcher expertise 2
... basic principle of a competitive enzyme immunoassay ... antigen and an labelled antigen bound to ... antiserum . The amount of enzyme conjugate ... antibody is inversely proportional to the concentration ...
... Progesterone (pregn-4-ene-3, 20-dione) is a C21 ... a double bond between C-4 and C-5 ... hormone which, in conjunction with estrogens, regulates,the ... it is particularly important in preparing the,endometrium ...
Microalbumin Turbidimetric Lipid / Protein Quantification 021-SDX001...
... known as Kininase II, is a dipeptidyl ... of at least 129,000. The structure of ... a polysaccharide residue and a zinc atom. ... types such as neuronal cells and renal ...
Medicine Products: